Merck's RotaTeq won China approval in April and a launch is underway, but meanwhile, the company is reducing its shipments to low-income countries.
Here is some news of note for the week: Apotex is dangling a $10 million reward in its CEO’s murder.
The FDA says a probable cancer-causing ingredient has been found in yet another blood pressure treatment in the U.S.
The FDA continues to find issues with Dr. Reddy’s oncology formulation facility at Duvvada, one of three cited in a warning letter.
Astellas will invest $255 million in production and R&D as it pushes into gene and cell therapies for cancer and other diseases.
Pfizer acknowledged that it continues to struggle with manufacturing at some Hospira plants, an issue that bodes ill for U.S. hospitals.
India's Glenmark is opening a $100 million plant in North Carolina to make generic drugs.
Merck's Gardasil generated $1 billion in Q3, prompting an analyst to wonder just how much the shot might be able to generate in the long run.
Aspen Pharmacare says it will invest nearly $235 million in a facility to manufacture sterile anesthetics.
EMA inspectors have uncovered big manufacturing and quality concerns at sterile injectables plant of Genfarma Laboratorio in Spain.